Sarepta Therapeutics (SRPT) Gross Margin (2017 - 2026)

Sarepta Therapeutics' Gross Margin history runs 10 years deep, the most recent figure standing at 85.12% for Q1 2026.

• In Q1 2026, Gross Margin rose 8829.0% year-over-year to 85.12%; the TTM figure through Mar 2026 stood at 62.88% (down 1208.0% YoY), while the FY2025 annual figure was 54.96%, down 2826.0% from the prior year.
• Gross Margin for Q1 2026 stood at 85.12%, up from 9.98% in the prior quarter.
• The five-year high for Gross Margin was 96.44% in Q4 2022, with the low at 3.17% in Q1 2025.
• The 5-year median for Gross Margin is 83.35% (2022), against an average of 74.43%.
• The sharpest annual moves came in 2025 and 2026: Gross Margin slumped 9095 bps in 2025, then jumped 8829 bps in 2026.
• Sarepta Therapeutics' Gross Margin stood at 96.44% in 2022, then decreased by 1 bps to 95.9% in 2023, then decreased by 17 bps to 79.91% in 2024, then sank by 88 bps to 9.98% in 2025, then jumped by 752 bps to 85.12% in 2026.
• Business Quant data shows SRPT's Gross Margin at 85.12% in Q1 2026, 9.98% in Q4 2025, and 62.25% in Q3 2025.